Back to Peptides

CJC-1295 with DAC

Well Studied

Long-Acting Growth Hormone Releasing Hormone Analog | Extended Release

Dose 1-2mg weekly
Frequency Once or twice weekly (e.g., Monday/Thursday for split dosing)
Cycle 8-12 weeks
Storage Lyophilized: 2-8°C refrigerated; Reconstituted: 2-8°C refrigerated, use within 30 days
Accumulation Plotter

Modified growth hormone releasing hormone engineered for extended duration via albumin-binding technology. DAC binds to albumin, extending half-life and providing continuous GHRH receptor stimulation.

Mechanism of Action

DAC binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation for sustained GH/IGF-1 elevation.

Key Benefits

  • Convenient weekly dosing
  • Sustained GH/IGF-1 elevation
  • 6-8 day half-life
  • Significant body composition changes
Molecular Weight
3,647.28 Da
Chain Length
30 amino acids
Type
GHRH analog with DAC
Amino Acid Sequence
One-letter: YADAIFTNSYRKVLAQLSARKLLQDILSRK
H₂N
Y 1
O ‖ C
N
A 2
O ‖ C
N
D 3
O ‖ C
N
A 4
O ‖ C
N
I 5
O ‖ C
N
F 6
O ‖ C
N
T 7
O ‖ C
N
N 8
O ‖ C
N
S 9
O ‖ C
N
Y 10
O ‖ C
N
R 11
O ‖ C
N
K 12
O ‖ C
N
V 13
O ‖ C
N
L 14
O ‖ C
N
A 15
O ‖ C
N
Q 16
O ‖ C
N
L 17
O ‖ C
N
S 18
O ‖ C
N
A 19
O ‖ C
N
R 20
O ‖ C
N
K 21
O ‖ C
N
L 22
O ‖ C
N
L 23
O ‖ C
N
Q 24
O ‖ C
N
D 25
O ‖ C
N
I 26
O ‖ C
N
L 27
O ‖ C
N
S 28
O ‖ C
N
R 29
O ‖ C
N
K 30
COOH
Tyr
1

Tyrosine

Position 1

Ala
2

Alanine

Position 2

Asp
3

Aspartic Acid

Position 3

Ala
4

Alanine

Position 4

Ile
5

Isoleucine

Position 5

Phe
6

Phenylalanine

Position 6

Thr
7

Threonine

Position 7

Asn
8

Asparagine

Position 8

Ser
9

Serine

Position 9

Tyr
10

Tyrosine

Position 10

Arg
11

Arginine

Position 11

Lys
12

Lysine

Position 12

Val
13

Valine

Position 13

Leu
14

Leucine

Position 14

Ala
15

Alanine

Position 15

Gln
16

Glutamine

Position 16

Leu
17

Leucine

Position 17

Ser
18

Serine

Position 18

Ala
19

Alanine

Position 19

Arg
20

Arginine

Position 20

Lys
21

Lysine

Position 21

Leu
22

Leucine

Position 22

Leu
23

Leucine

Position 23

Gln
24

Glutamine

Position 24

Asp
25

Aspartic Acid

Position 25

Ile
26

Isoleucine

Position 26

Leu
27

Leucine

Position 27

Ser
28

Serine

Position 28

Arg
29

Arginine

Position 29

Lys
30

Lysine

Position 30

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified

Growth Hormone

  • Sustained GH Elevation

    Continuous growth hormone release for 6-8 days per injection.

  • IGF-1 Optimization

    Significantly elevates IGF-1 levels for extended periods.

  • Convenience Protocol

    Weekly dosing ideal for simple administration.

Body Composition

  • Fat Loss Enhancement

    Continuous GH elevation promotes lipolysis and fat metabolism.

  • Lean Mass Gains

    Sustained anabolic environment supports muscle protein synthesis.

Anti-Aging

  • Recovery Enhancement

    Accelerated healing and recovery from exercise or injury.

Subcutaneous injection is the preferred route for DAC variant.

GoalDoseFrequencyRoute
Conservative Anti-Aging1mgOnce weeklySubQ
Standard Protocol2mgOnce weeklySubQ
Split Dosing1mgTwice weekly (Mon/Thu)SubQ
Loading Protocol2mg first week, then 1mgWeeklySubQ

Reconstitution Instructions

Materials Needed:
  • CJC-1295 with DAC peptide vial
  • Bacteriostatic water (2-5mL)
  • Insulin or 1mL syringes
  • Alcohol prep pads
  1. 1 Clean both vial tops with alcohol and dry completely
  2. 2 2mg vial: Add 1mL bacteriostatic water (creates 2mg/mL)
  3. 3 5mg vial: Add 2.5mL bacteriostatic water (creates 2mg/mL)
  4. 4 Inject water slowly to prevent foaming
  5. 5 Let sit 5 minutes before gently rolling to mix
  6. 6 Solution may appear slightly cloudy initially
  7. 7 Label with date and concentration immediately
Ipamorelin

Continuous GH elevation may reduce synergistic benefits of pulsatile protocols.

monitor
GHRP-6

GHRP pulse effects diminished with continuous GH elevation.

monitor
CJC-1295 (without DAC)

Never combine different variants; choose based on desired release pattern.

avoid
MK-677

Both provide continuous GH elevation; combination risks excessive levels.

avoid
Tesamorelin

Both are GHRH analogs; no additional benefit and potential receptor competition.

avoid
HGH

Defeats purpose and may suppress natural production.

avoid
Sermorelin

CJC-1295 DAC is already more potent and long-lasting.

monitor
Week 1

Possible water retention, improved sleep, increased appetite

Week 2-3

Noticeable recovery improvements, some report joint discomfort

Week 4-6

Visible body composition changes, increased vascularity

Week 6-8

Continued improvements but watch for desensitization signs

Post-cycle

Most gains maintained; IGF-1 returns to baseline in 2-3 weeks

Common Side Effects

  • Water retention
  • Joint pain
  • Carpal tunnel symptoms

Stop Signs - Discontinue if:

  • Severe joint pain or carpal tunnel syndrome
  • Excessive water retention affecting daily life
  • Numbness or tingling in extremities
  • Significant blood glucose dysregulation
  • Signs of acromegaly (jaw growth, hand/feet enlargement)
  • Persistent lethargy indicating adrenal effects

Contraindications

  • Diabetes history
  • Cancer history
  • Predisposed sleep apnea

Good Signs

  • High purity requirement (>98%); impurities cause more side effects
  • Proper DAC labeling; legitimate products clearly state 'with DAC'

Warning Signs

  • Higher cost than non-DAC (2-3x more due to complex manufacturing)
  • Foaming during mixing is normal for DAC peptides; wait for foam to settle

Bad Signs

  • Extremely cheap pricing (if priced similar to non-DAC, likely mislabeled)
  • Clear solution immediately (should be slightly cloudy initially)
  • Prolonged Growth Hormone Elevation with CJC-1295 DAC
    (2006)

    12 subjects; sustained GH and IGF-1 elevation for 6-10 days post-injection with peak 2-4x baseline.

  • Dose-Response Relationship of CJC-1295 DAC
    (2008)

    48 subjects, 90 days. Optimal dosing 1-2mg weekly; dose-dependent IGF-1 increases but higher side effects above 2mg.

  • Long-term Effects on GH/IGF-1 Axis
    (2012)

    6-month animal model. Sustained IGF-1 elevation but evidence of reduced GH pulse amplitude suggesting desensitization.

  • Comparative Pharmacokinetics: DAC vs Non-DAC Variants
    (2015)

    DAC: 120-hour half-life vs non-DAC: 30-minute; non-DAC preserves more physiological patterns.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.